Tuberculosis (TB) remains a significant global health challenge, with an estimated 10 million new cases and 1.4 million deaths annually. Despite advances in healthcare, the accurate and timely diagnosis of TB remains a challenge. This article provides a comprehensive overview of the contemporary diagnostic approaches for TB.
Microbiological testing remains the gold standard for TB diagnosis. The method involves the isolation of Mycobacterium tuberculosis from sputum samples and subsequent identification through culture and sensitivity testing. Modern advancements include the use of liquid culture systems and nucleic acid amplification tests (NAATs), which offer faster and more accurate results.
Molecular diagnostic techniques, such as the GeneXpert MTB/RIF assay, have revolutionized TB diagnostics. This automated, cartridge-based nucleic acid amplification test can detect TB and rifampicin resistance within two hours, significantly reducing diagnosis time and facilitating early initiation of treatment.
Imaging techniques like chest radiography and computed tomography (CT) scans play a crucial role in TB diagnosis, particularly in patients unable to produce sputum or those with extrapulmonary TB. These tools provide visual evidence of disease manifestation and progression, aiding in diagnosis and treatment planning.
Immunological tests such as the Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs) are used to detect latent TB infection. These tests measure the immune response to TB antigens, providing an indirect indication of TB infection. However, they cannot differentiate between active and latent TB, limiting their diagnostic utility.
While significant strides have been made in TB diagnostics, challenges remain, particularly in resource-limited settings and in diagnosing extrapulmonary and drug-resistant TB. Continued research and development of more accurate, rapid, and cost-effective diagnostic tools are crucial to combat this global health threat.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation